Enoxaparin-Associated Adverse Events

Hematologic and Hemorrhagic Complications

Major bleeding occurs in 0.1% to 0.7% of patients undergoing orthopedic surgery, with rates comparable to unfractionated heparin, according to the American College of Chest Physicians 1
Clinically relevant non-major bleeding events occur in 2.6% to 3.3% of patients, as reported by the American College of Chest Physicians 1
Intracranial hemorrhage risk increases significantly in elderly patients (>75 years) when enoxaparin is administered pre-hospital with fibrinolytic therapy, as noted by the European Society of Cardiology 2
Non-cerebral bleeding complications increase when enoxaparin is used with fibrinolytic agents, though net clinical benefit may still favor enoxaparin, according to the European Society of Cardiology 2
Heparin-induced thrombocytopenia (HIT) is an antibody-mediated reaction that may cause arterial or venous thrombosis, as described by the American Heart Association 3
Hospital-acquired thrombocytopenia (platelet counts <150,000) occurs in approximately 10-13% of patients receiving heparin-based regimens, as reported by the American Heart Association 3

Nausea, vomiting, and constipation are the most frequent drug-related adverse events, occurring in 12-20% of patients, similar to rates observed with unfractionated heparin, according to the American College of Chest Physicians 1

No evidence of drug-associated liver toxicity was found in phase III trials lasting up to 5 weeks, as reported by the American College of Chest Physicians 1
Elevated liver enzymes occur at low rates similar to enoxaparin comparators, according to the American College of Chest Physicians 1
Cardiovascular events while on treatment range between 0.1% and 0.7%, similar to enoxaparin, as noted by the American College of Chest Physicians 1

Enoxaparin has delayed clearance in renal dysfunction due to its longer half-life compared to unfractionated heparin, as described by the American Heart Association 3
Pre-hospital administration in elderly patients significantly increases intracranial hemorrhage risk when combined with fibrinolytics, according to the European Society of Cardiology 2

Enoxaparin is unlikely to be dialyzable due to high plasma protein binding, as reported by the American College of Chest Physicians 1
In cases of active bleeding, discontinuation and administration of blood products may be necessary, according to the American College of Chest Physicians 1
Concomitant use of NSAIDs, aspirin, or other antiplatelet agents does not significantly increase bleeding rates in pooled analyses, as noted by the American College of Chest Physicians 1

Patients with high risk of venous thromboembolism (VTE) who are unable to move independently, have a history of VTE, dehydration, or comorbidities such as cancer, may benefit from enoxaparina therapy 4
The American Heart Association recommends enoxaparina for patients with acute coronary syndromes, including unstable angina or non-ST-elevation myocardial infarction (NSTEMI) 5
Enoxaparina is indicated for patients with ST-elevation myocardial infarction (STEMI) undergoing fibrinolysis or primary percutaneous coronary intervention (PCI) 6

For patients with severe renal impairment (creatinine clearance <30 mL/min), the dose of enoxaparina should be adjusted to 1mg/kg subcutaneously once daily 6
For patients ≤75 years with acute coronary syndromes, a dose of 30mg intravenously followed by 1mg/kg subcutaneously every 12 hours is recommended 6
For patients >75 years with acute coronary syndromes, a dose of 0.75mg/kg subcutaneously every 12 hours without initial bolus is recommended 6

The American Urological Association notes that enoxaparina is contraindicated in patients with thrombocytopenia and positive in vitro test for antiplatelet antibodies in the presence of the drug 7
Enoxaparina is contraindicated in patients with known hypersensitivity to the drug, heparin, sulfites, benzyl alcohol, or pork products 7
Patients with active major bleeding, severe renal impairment, or hepatic insufficiency with elevated INR (>1.5) should be cautious when using enoxaparina 7

After initiating enoxaparina, hemoglobin, hematocrit, and platelet count should be monitored every 2-3 days for the first 14 days 8
When transitioning to other anticoagulants, such as acenocoumarol, enoxaparina should be continued until the INR reaches the therapeutic range (2.0-3.0) for two consecutive days 9